University of Science and Technology of China
Hefei, Anhui, 210000, China
NCT Number: NCT05416853
Background: For moderate to severe carotid artery atherosclerotic stenosis, in the past decades, carotid artery stenting (CAS) has been an alternative to carotid endarterectomy (CEA) for the treatment of carotid artery stenosis. The transfemoral artery (TFA) using Seldinger's technique has been the most commonly used approach for CAS. The radial artery is an ideal puncture site for cerebrovascular intervention. Studies have shown that nerve intervention through radial artery approach can complete most cerebrovascular intervention procedures, including cerebral angiography, carotid artery stent implantation, vertebral artery stent implantation, intracranial artery stent implantation, mechanical thrombectomy, aspiration, intra-arterial thrombolysis and so on. However, the current studies are based on single center small sample studies, and there has been still a lack of large sample randomized controlled experiments to verify the safety and effectiveness of CAS in transradial artery (TRA) .
Objective: To evaluate the efficacy and safety of CAS via TRA in patients with carotid artery stenosis through a multicenter, prospective and randomized study.
Study design: This study is a randomized, open label, multicenter, parallel controlled trial. A non-inferiority test is performed to compare the primary end point between the experimental group and the control group. The experimental group will undergo carotid stent implantation via radial artery approach, while the control group will use femoral artery approach.
Study population: Adult patients with symptomatic carotid-artery stenosis ≥50% or asymptomatic stenosis ≥70%.
Study outcomes: Primary end points: The incidence of death, or new-onset stroke, or myocardial infarction, or severe hemorrhage events within 30 days post-procedure Secondary end points:1.The incidence of death, or new-onset stroke, or myocardial infarction, or severe hemorrhage events within 48 hours post-procedure. 2. The incidence of death, new-onset stroke and myocardial infarction within 48 hours / 30 days post-procedure. 3. The incidence of death within 48 hours / 30 days post-procedure. 4. The incidence of new-onset stroke within 48 hours / 30 days post-procedure. 5. The incidence of myocardial infarction within 48 hours / 30 days post-procedure. 6. The incidence of severe hemorrhage events within 48 hours / 30 days post-procedure. Other end points: 1. Successful rate of cerebral angiography. 2. Successful rate of CAS. 3. Degree of patient-reported comfort. 4. Operation time. 5. NIHSS score changes within 5-7 days post-procedure. 6. mRS score score within 30 days post-procedure. Safety outcomes: 1.Occurrence of all adverse events. 2. AEs related to operation and device. 3. Incidence of adverse event of special interest.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Hefei, Anhui, 210000, China
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
CAS involves insertion of a catheter or tube into an artery in the groin or the radial, and then threading the catheter through the arteries of the body to the location of the plaque within the carotid artery in the neck. A stent is then placed to cover the plaque and hold the artery open.
Time frame: 30 days
The composite end point event is defined as any one of death, new-onset stroke, myocardial infarction, and severe hemorrhage events within 30 days.
Time frame: 48 hours
The composite end point event is defined as any one of death, new-onset stroke, myocardial infarction, and severe hemorrhage events within 48 hours
Time frame: 48 hours / 30 days
The incidence of death, new-onset stroke and myocardial infarction within 48 hours / 30 days post-procedure
Time frame: 48 hours / 30 days
The incidence of death within 48 hours / 30 days post-procedure
Time frame: 48 hours / 30 days
The incidence of new-onset stroke within 48 hours / 30 days post-procedure
Time frame: 48 hours / 30 days
The incidence of myocardial infarction within 48 hours / 30 days post-procedure
Time frame: 48 hours / 30 days
The incidence of severe hemorrhage events within 48 hours / 30 days post-procedure
Time frame: 24 hours
successful puncture and sheathing; the catheter is successfully delivered to the aortic arch and aortography is completed; angiography of the target vessel is performed using standard operating techniques.
Time frame: 24 hours
Successful carotid artery stenting (CAS) is defined as: access devices can be established, interventional devices can reach the lesion site, operations such as distal brain protection device release, balloon expansion and stent implantation, and withdraw protection device can be completed successfully.
Time frame: 24 hours
The comfort scale adopts the simplified General Comfort Questionnaire (GCQ)developed by nursing expert Kolcaba. The scale is scored by level 1 to 4 Likert scale, with a score range of 28-112 points. The lowest score is 28 points and the highest score is 112 points. The higher the score, the higher the comfort. A total score of < 60 is low comfort, a total score of 60-90 is moderate comfort, and a total score of > 90 is high comfort.
Time frame: 24 hours
Operation time is defined as the time from arterial puncture to completion of DSA or CAS.
Time frame: 5-7 days post-procedure
NIHSS score changes within 5-7 days post-procedure; NIHSS is a stroke severity score composed of 11 items (range from 0 to 42, higher values indicate more severe deficits).
Time frame: 30 days
mRS is short for modified Ranking score (ranging from 0 to 6, with higher values indicating a worse functional outcome).
Time frame: 30 days
AEs are defined as any undesirable medical experience occurring to a subject during the study, from the time of informed consent signed to the end of the trial.
Time frame: 24 hours
AEs related to operation and device are defined as those related to operation procedure and device determined by investigators.
Time frame: 30 days
AESI are defined as events that require special attention when evaluating safety. AESI includes: 1) pseudoaneurysms requiring ultrasound-guided compression or thrombin injections or surgical treatment; 2) hematoma requiring prolonged hospital stay; 3) limb ischemia and nerve injury adjacent to the blood vessels. 4) radial artery occlusion or thrombosis confirmed by ultrasound.
The First Affiliated Hospital of University of Science and Technology of China
Other
Radial Versus Femoral Access For Carotid Artery Stenting In Patients With Carotid-Artery Stenosis :a Prospective, Randomized, Multicenter, Noninferiority Trial
Acronym: RACE-CAS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03333330
Arterial Occlusive Diseases, Arteriosclerosis
View Trial DetailsNCT05300737
Arterial Occlusive Diseases, Brain Diseases
Hartford, Connecticut, United States
View Trial DetailsNCT06947720
Arterial Occlusive Diseases, Brain Diseases
Beijing, Beijing Municipality, China
View Trial DetailsNCT06541691
Arterial Occlusive Diseases, Arteriosclerosis
Tehran, Tehran Province, Iran
View Trial Details